ALTAMIRATHERAPEUTICS.COM: Keyword Density Checker

Total words: 811 | 2-word phrases: 204 | 3-word phrases: 228 | 4-word phrases: 236

PAGE INFO

Title	Try to keep the title under 60 characters (52 characters) Altamira Therapeutics: Targeting unmet medical needs
Description	Try to keep the meta description between 50 - 160 characters (107 characters) Altamira Therapeutics is active in RNA therapeutics, allergy and viral infections, and inner ear disorders.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (28 characters) Targeting unmetmedical needs

#	Keyword	Frequency	Density
1	rnabased therapeutics for	4	1.75%
2	therapeutics is dedicated	4	1.75%
3	infections and inner	4	1.75%
4	inner ear therapeutics	4	1.75%
5	is dedicated to	4	1.75%
6	programs in preclinical	3	1.32%
7	developing rnabased therapeutics	3	1.32%
8	for kras driven	3	1.32%
9	am401 for kras	3	1.32%
10	concept am401 for	3	1.32%
11	of concept am401	3	1.32%
12	proof of concept	3	1.32%
13	beyond in vivo	3	1.32%
14	development beyond in	3	1.32%
15	sirna programs in	3	1.32%
16	altamira therapeutics is	3	1.32%
17	flagship sirna programs	3	1.32%
18	and am411 for	3	1.32%
19	delivery platforms the	3	1.32%
20	oligophore™semaphore™ delivery platforms	3	1.32%
21	unmet medical needs	3	1.32%
22	medical needs altamira	3	1.32%
23	for extrahepatic targets	3	1.32%
24	therapeutics for extrahepatic	3	1.32%
25	company currently has	3	1.32%
26	two flagship sirna	3	1.32%
27	am411 for rheumatoid	3	1.32%
28	the process of	3	1.32%
29	and inner ear	3	1.32%
30	allergology and viral	3	1.32%

#	Keyword	Frequency	Density
1	therapeutics is dedicated to	4	1.69%
2	proof of concept am401	3	1.27%
3	oligophore™semaphore™ delivery platforms the	3	1.27%
4	andor outlicensing its legacy	3	1.27%
5	outlicensing its legacy assets	3	1.27%
6	its legacy assets in	3	1.27%
7	in the process of	3	1.27%
8	infections and inner ear	3	1.27%
9	and inner ear therapeutics	3	1.27%
10	altamira therapeutics is dedicated	3	1.27%
11	additionally the company is	3	1.27%
12	arthritis additionally the company	3	1.27%
13	developing rnabased therapeutics for	3	1.27%
14	the process of divesting	3	1.27%
15	therapeutics for extrahepatic targets	3	1.27%
16	rnabased therapeutics for extrahepatic	3	1.27%
17	and am411 for rheumatoid	3	1.27%
18	flagship sirna programs in	3	1.27%
19	concept am401 for kras	3	1.27%
20	am401 for kras driven	3	1.27%
21	development beyond in vivo	3	1.27%
22	sirna programs in preclinical	3	1.27%
23	of concept am401 for	3	1.27%
24	two flagship sirna programs	3	1.27%
25	cancer and am411 for	3	1.27%
26	the company is in	2	0.85%
27	the company currently has	2	0.85%
28	for kras driven cancer	2	0.85%
29	driven cancer and am411	2	0.85%
30	is in the process	2	0.85%
31	company is in the	2	0.85%
32	targeting unmet medical needs	2	0.85%
33	is dedicated to developing	2	0.85%
34	unmet medical needs altamira	2	0.85%
35	preclinical development beyond in	2	0.85%
36	in preclinical development beyond	2	0.85%
37	delivery platforms the company	2	0.85%
38	needs altamira therapeutics is	2	0.85%
39	programs in preclinical development	2	0.85%
40	kras driven cancer and	2	0.85%